Found: 31
Select item for more details and to access through your institution.
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 2, p. 291, doi. 10.1007/s10637-018-0656-z
- By:
- Publication type:
- Article
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 903, doi. 10.1007/s10637-018-0617-6
- By:
- Publication type:
- Article
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1399889
- By:
- Publication type:
- Article
Wild-type Transthyretin Amyloidosis with Diffuse Alveolar-septal Amyloidosis Diagnosed by a Transbronchial Lung Biopsy.
- Published in:
- Internal Medicine, 2022, v. 61, n. 14, p. 2203, doi. 10.2169/internalmedicine.8521-21
- By:
- Publication type:
- Article
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 6, p. 2475, doi. 10.1007/s00432-022-04125-8
- By:
- Publication type:
- Article
Phase II Study of S‐1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non‐Small Cell Lung Cancer.
- Published in:
- Oncologist, 2019, v. 24, n. 8, p. 1033, doi. 10.1634/theoncologist.2019-0290
- By:
- Publication type:
- Article
A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer.
- Published in:
- Oncologist, 2019, v. 24, n. 4, p. 459, doi. 10.1634/theoncologist.2018-0858
- By:
- Publication type:
- Article
Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study).
- Published in:
- 2019
- By:
- Publication type:
- journal article
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 4, p. 1521, doi. 10.1002/cam4.2037
- By:
- Publication type:
- Article
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR‐TKI in non–small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.
- Published in:
- Thoracic Cancer, 2023, v. 14, n. 11, p. 1004, doi. 10.1111/1759-7714.14836
- By:
- Publication type:
- Article
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum–Etoposide Chemotherapy.
- Published in:
- Drugs & Aging, 2023, v. 40, n. 6, p. 563, doi. 10.1007/s40266-023-01034-4
- By:
- Publication type:
- Article
Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study).
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920927841
- By:
- Publication type:
- Article
Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 14, p. 15117, doi. 10.1002/cam4.6184
- By:
- Publication type:
- Article
Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management.
- Published in:
- BioMed Research International, 2018, v. 2018, p. 1, doi. 10.1155/2018/8202971
- By:
- Publication type:
- Article
Phase II Trial of Weekly Gemcitabine and Split-dose Cisplatin for Advanced Non-small-cell Lung Cancer.
- Published in:
- Japanese Journal of Clinical Oncology, 2009, v. 39, n. 12, p. 779, doi. 10.1093/jjco/hyp111
- By:
- Publication type:
- Article
Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 3, p. 526, doi. 10.1111/1759-7714.12969
- By:
- Publication type:
- Article
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1699, doi. 10.1007/s00262-023-03370-1
- By:
- Publication type:
- Article
Procaterol-stimulated Increases in Ciliary Bend Amplitude and Ciliary Beat Frequency in Mouse Bronchioles.
- Published in:
- Cellular Physiology & Biochemistry (Karger AG), 2012, v. 29, n. 3/4, p. 511, doi. 10.1159/000338505
- By:
- Publication type:
- Article
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1348034
- By:
- Publication type:
- Article
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
- Published in:
- Cancers, 2023, v. 15, n. 20, p. 4988, doi. 10.3390/cancers15204988
- By:
- Publication type:
- Article
Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions.
- Published in:
- Cancers, 2019, v. 11, n. 3, p. 410, doi. 10.3390/cancers11030410
- By:
- Publication type:
- Article
Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.
- Published in:
- Cancers, 2019, v. 11, n. 3, p. 365, doi. 10.3390/cancers11030365
- By:
- Publication type:
- Article
Tumor Neovascularization and Developments in Therapeutics.
- Published in:
- Cancers, 2019, v. 11, n. 3, p. 316, doi. 10.3390/cancers11030316
- By:
- Publication type:
- Article
Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients.
- Published in:
- Cancers, 2019, v. 11, n. 3, p. 282, doi. 10.3390/cancers11030282
- By:
- Publication type:
- Article
Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
- Published in:
- Journal of Clinical Medicine, 2019, v. 8, n. 4, p. 450, doi. 10.3390/jcm8040450
- By:
- Publication type:
- Article
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 7, p. e2322915, doi. 10.1001/jamanetworkopen.2023.22915
- By:
- Publication type:
- Article
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1303543
- By:
- Publication type:
- Article
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 3, p. 411, doi. 10.1007/s11523-024-01045-0
- By:
- Publication type:
- Article
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 6, p. 915, doi. 10.1007/s11523-023-01012-1
- By:
- Publication type:
- Article
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 5, p. 657, doi. 10.1007/s11523-023-00991-5
- By:
- Publication type:
- Article